SEREX, Proteomex, AMIDA, and beyond: Serological screening technologies for target identification

Area of Science:

• Oncology
• Immunology
• Biochemistry

Background:

• Cancer remains a significant global health challenge despite extensive research.
• Identifying reliable biomarkers is key for early cancer diagnosis and developing novel immunotherapies.
• Tumor-associated antigens (TAA) elicit immune responses, leading to specific serum antibodies.

Purpose of the Study:

• To review and compare major serological methods for identifying cancer biomarkers.
• To summarize the clinical progress and applications of serologically identified TAA.
• To emphasize the role of serum antibodies in cancer antigen discovery.

Main Methods:

• Focuses on three prominent serological target identification techniques: SEREX (Serological Expression Cloning), Proteomex, and AMIDA (Antibody-Mediated Antigen Detection Assay).
• Discusses the principles and utility of each method in isolating antigens recognized by cancer patient antibodies.
• Reviews the process of identifying tumor-specific antigens through humoral immune responses.

Main Results:

• Serological methods enable the isolation and identification of cancer-specific antigens from patient serum.
• These identified antigens serve as potential biomarkers for diagnosis and targets for immunotherapy.
• Significant advancements have been made in the clinical application of serologically discovered TAA.

Conclusions:

• Serological approaches are powerful tools for discovering tumor-associated antigens (TAA).
• The reviewed methods (SEREX, Proteomex, AMIDA) have contributed to identifying clinically relevant cancer biomarkers.
• Further development and application of these techniques promise improved cancer diagnostics and therapeutics.